You are now leaving the Lilly Medical website
The link you clicked on will take you to a site maintained by a third party, which is solely responsible for its content. Lilly USA, LLC does not control, influence, or endorse this site, and the opinions, claims, or comments expressed on this site should not be attributed to Lilly USA, LLC. Lilly USA, LLC is not responsible for the privacy policy of any third-party websites. We encourage you to read the privacy policy of every website you visit.
Click "Continue" to proceed or "Return" to return to Lilly Medical
If you wish to report an adverse event or product complaint, please call 1-800-LILLYRX (1-800-545-5979)
Foundayo ™ (orforglipron) tablet
0.8 mg / 2.5 mg / 5.5 mg / 9 mg / 14.5 mg / 17.2 mg
This information is provided in response to your request. Resources may contain information about doses, uses, formulations and populations different from product labeling. See Prescribing Information above, if applicable.
What dosages of Foundayo™ (orforglipron) capsules are equivalent to the tablet dosages?
Orforglipron tablets and capsules are different formulations with different strengths. Capsule doses of 1, 3, 6, 12, 24, and 36 mg correspond to tablet doses of 0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg. Equivalent doses provide comparable systemic exposure.
See important safety information, including boxed warning, in the attached prescribing information.
Content Overview
- Why Are the Approved Doses of Orforglipron Different From the Doses Studied in Clinical Trials?
- Is There a Difference in the Efficacy and Safety of Orforglipron Capsules and Tablets?
- Enclosed Prescribing Information
- References
Why Are the Approved Doses of Orforglipron Different From the Doses Studied in Clinical Trials?
The orforglipron capsule formulation was the initial oral dosage form developed and studied in the ATTAIN clinical program.1,2
The orforglipron tablets were later developed to allow increased flexibility of treatment options.3
Capsules and tablets are not substitutable on a mg-per-mg basis. Given the difference in drug absorption between the 2 orforglipron formulations, the tablet dose strengths are numerically lower than the capsule dose strengths, particularly at higher doses.3,4
Orforglipron tablets, and not capsules, are approved and available in the United States.5
Is There a Difference in the Efficacy and Safety of Orforglipron Capsules and Tablets?
In a phase 1 study, equivalence between capsules and dose-adjusted tablets was reported across all 6 orforglipron doses.
Study participants received each orforglipron capsule and tablet dose strength once daily for 7 days in the fasted state at capsule doses of 1, 3, 6, 12, 24, or 36 mg and corresponding tablet doses of 0.8, 2.5, 5.5, 9, 14.5, and 17.2 mg.
The primary endpoint was steady-state area under the concentration–time curve from 0 to 24 h (AUC0–24,ss) and steady-state maximum observed drug concentration (Cmax,ss).
Bioequivalence was demonstrated between capsules and dose-adjusted tablets across all 6 doses.
The 90% confidence interval of the ratios of the geometric least-squares means of AUC0–24,ss and Cmax,ss between each capsule dose and corresponding tablet dose met the predefined criteria for bioequivalence.
The safety profiles were similar between tablets and capsules, with no apparent differences or trends in the incidence of treatment-emergent adverse events by presentation or with increasing dose.
Given the demonstrated pharmacokinetic equivalence, it is expected that the safety and efficacy of the orforglipron capsule doses studied in the phase 3 studies will be equivalent to that of the corresponding orforglipron tablet doses (Table 1).1
| Table 1. Equivalent Orforglipron Tablet and Capsule Strengths1 | |
|---|---|
| Capsule Dose | Corresponding Tablet Dose |
| 1 mg | 0.8 mg |
| 3 mg | 2.5 mg |
| 6 mg | 5.5 mg |
| 12 mg | 9 mg |
| 24 mg | 14.5 mg |
| 36 mg | 17.2 mg |
Enclosed Prescribing Information
FOUNDAYO™ (orforglipron) tablets, for oral use, Lilly
References
The published references below are available by contacting 1-800-LillyRx (1-800-545-5979).
- Wharton S, Aronne LJ, Stefanski A, et al; ATTAIN-1 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist for obesity treatment. N Engl J Med. 2025;393(18):1796-1806. https://doi.org/10.1056/NEJMoa2511774
- Horn DB, Ryan DH, Giljanovic Kis S, et al; ATTAIN-2 Trial Investigators. Orforglipron, an oral small-molecule GLP-1 receptor agonist, for the treatment of obesity in people with type 2 diabetes (ATTAIN-2): a phase 3, double-blind, randomised, multicentre, placebo-controlled trial. Lancet. 2025;406(10522):2927-2944. https://doi.org/10.1016/S0140-6736(25)02165-8.
- Ma X, Li YG, Raha S, et al. Pharmacokinetic bioequivalence of orforglipron tablets and capsules in healthy participants with obesity or overweight. Diabetes Obes Metab. Published online April 17, 2026. https://doi.org/10.1111/dom.70783
- Data on file, Eli Lilly and Company and/or one of its subsidiaries.
- Foundayo [package insert]. Indianapolis, IN: Eli Lilly and Company; 2026.
Date of Last Review: April 22, 2026